Aurinia Pharmaceuticals Inc
AUPH7.490USD
+0.010+0.13%
收盘 07/02, 16:00（美东）报价延迟15分钟
1.03B总市值
25.89市盈率 TTM
关于 Aurinia Pharmaceuticals Inc 公司
Aurinia Pharmaceuticals Inc. 是一家完全整合的生物制药公司。该公司专注于为患有自身免疫性疾病且医疗需求尚未得到满足的患者提供治疗。该公司已开发出 LUPKYNIS（voclosporin），这是一种用于治疗活动性狼疮性肾炎 (LN) 成人患者的口服疗法，并继续开展临床和监管活动以支持 LUPKYNIS 开发计划。该公司主要致力于开发其管线资产 AUR200，这是一种针对 BAFF（B 细胞活化因子）和 APRIL（增殖诱导配体）的差异化、潜在的下一代自身免疫性疾病疗法。该公司与大塚制药株式会社 (Otsuka) 签订了合同，作为合作伙伴在大塚地区开发和商业化 LUPKYNIS。该公司主要向专科药房和专科分销商以及其美国以外的合作伙伴大塚销售 LUPKYNIS（voclosporin）。
公司简介
公司代码AUPH
公司名称Aurinia Pharmaceuticals Inc
上市日期Jul 16, 2001
成立日期2009
CEOMr. Peter S. Greenleaf
员工数量130
证券类型Ordinary Share
年结日Jul 16
公司地址#140, 14315 - 118 Avenue
城市EDMONTON
上市交易所NASDAQ Global Market Consolidated
国家Canada
邮编T5L 4S6
电话12507442487
网址https://www.auriniapharma.com
公司代码AUPH
上市日期Jul 16, 2001
成立日期2009
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
667.87K
+16.06%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
176.21K
+23.75%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-17.94%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-93.15%
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Andrea Christopher
Ms. Andrea Christopher
Executive Director, Corporate Communications and Investor Relations
Executive Director, Corporate Communications and Investor Relations
--
--
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin Tang
Mr. Kevin Tang
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. David R.W Jayne, M.D.
Dr. David R.W Jayne, M.D.
Independent Director
Independent Director
--
--
Mr. Craig Johnson
Mr. Craig Johnson
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
667.87K
+16.06%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
176.21K
+23.75%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-17.94%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-93.15%
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Andrea Christopher
Ms. Andrea Christopher
Executive Director, Corporate Communications and Investor Relations
Executive Director, Corporate Communications and Investor Relations
--
--
收入明细
单位: USD更新时间: 7 小时前
单位: USD更新时间: 7 小时前
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
US
210.09M
89.35%
Japan
25.04M
10.65%
Other
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 7月2日 周三
更新时间: 7月2日 周三
持股股东
股东类型
持股股东
持股股东
占比
Tang Capital Management, LLC
7.42%
ILJIN SNT Co., Ltd.
6.57%
BlackRock Institutional Trust Company, N.A.
5.53%
Armistice Capital LLC
3.70%
New Enterprise Associates (NEA)
2.94%
Other
73.84%
持股股东
持股股东
占比
Tang Capital Management, LLC
7.42%
ILJIN SNT Co., Ltd.
6.57%
BlackRock Institutional Trust Company, N.A.
5.53%
Armistice Capital LLC
3.70%
New Enterprise Associates (NEA)
2.94%
Other
73.84%
股东类型
持股股东
占比
Hedge Fund
14.35%
Investment Advisor
12.78%
Investment Advisor/Hedge Fund
12.71%
Corporation
6.57%
Venture Capital
3.02%
Research Firm
2.96%
Individual Investor
2.80%
Pension Fund
0.52%
Bank and Trust
0.35%
Other
43.95%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
436
77.25M
57.17%
-345.00
2025Q1
457
75.49M
55.51%
-3.25M
2024Q4
454
71.04M
51.53%
-9.95M
2024Q3
449
70.86M
49.85%
-8.98M
2024Q2
452
69.33M
48.80%
-9.83M
2024Q1
446
69.12M
48.16%
-8.26M
2023Q4
460
67.04M
46.69%
-7.24M
2023Q3
469
63.17M
44.06%
-14.31M
2023Q2
493
65.34M
45.61%
-23.55M
2023Q1
499
65.33M
45.73%
-27.23M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Tang Capital Management, LLC
10.03M
7.42%
+1.60M
+18.98%
Mar 31, 2025
ILJIN SNT Co., Ltd.
8.88M
6.57%
+2.48M
+38.78%
Apr 12, 2025
BlackRock Institutional Trust Company, N.A.
7.47M
5.53%
-150.03K
-1.97%
Mar 31, 2025
Armistice Capital LLC
5.00M
3.7%
-1.40M
-21.88%
Mar 31, 2025
New Enterprise Associates (NEA)
3.97M
2.94%
--
--
Mar 31, 2025
State Street Global Advisors (US)
2.85M
2.11%
-66.87K
-2.29%
Mar 31, 2025
The Vanguard Group, Inc.
1.94M
1.44%
+241.86K
+14.20%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.74M
1.29%
+754.77K
+76.56%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.73M
1.28%
-30.09K
-1.71%
Mar 31, 2025
Arrowstreet Capital, Limited Partnership
1.64M
1.21%
+564.52K
+52.47%
Mar 31, 2025
查看更多
持股ETF
更新时间: 18 小时前
更新时间: 18 小时前
机构名称
占比
Virtus LifeSci Biotech Products ETF
1.48%
ALPS Medical Breakthroughs ETF
0.93%
Janus Henderson Small Cap Growth Alpha ETF
0.7%
SPDR S&P International Small Cap ETF
0.14%
Invesco Nasdaq Biotechnology ETF
0.12%
ProShares Ultra Nasdaq Biotechnology
0.12%
Vanguard US Momentum Factor ETF
0.1%
iShares Biotechnology ETF
0.1%
Vanguard US Multifactor ETF
0.1%
Avantis US Small Cap Equity ETF
0.09%
查看更多
Virtus LifeSci Biotech Products ETF
占比1.48%
ALPS Medical Breakthroughs ETF
占比0.93%
Janus Henderson Small Cap Growth Alpha ETF
占比0.7%
SPDR S&P International Small Cap ETF
占比0.14%
Invesco Nasdaq Biotechnology ETF
占比0.12%
ProShares Ultra Nasdaq Biotechnology
占比0.12%
Vanguard US Momentum Factor ETF
占比0.1%
iShares Biotechnology ETF
占比0.1%
Vanguard US Multifactor ETF
占比0.1%
Avantis US Small Cap Equity ETF
占比0.09%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
